Cyberonics Announces Expansion Of Share Repurchase Program By An Additional One Million Shares

 Cyberonics Announces Expansion Of Share Repurchase Program By An Additional
                              One Million Shares

PR Newswire

HOUSTON, Jan. 28, 2013

HOUSTON, Jan. 28, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today
announced that its board of directors has approved a new share repurchase
program of one million shares.

The company's board of directors had previously authorized repurchases of
shares in February 2008, February, 2010, June 2011 and November 2011. This new
authorization is expected to commence on completion of the current program.

Since February 2008, and through October 26, 2012, the company has repurchased
over 2.9 million shares for approximately $80 million.

About Cyberonics, Inc. and the VNS Therapy^® System

Cyberonics, Inc. is a medical technology company with core expertise in
neuromodulation. The company developed and markets the VNS Therapy System,
which is FDA-approved for the treatment of refractory epilepsy and
treatment-resistant depression. The VNS Therapy System uses a surgically
implanted medical device that delivers pulsed electrical signals to the vagus
nerve. Cyberonics markets the VNS Therapy System in selected markets
worldwide.

Additional information on Cyberonics and the VNS Therapy System is available
at www.cyberonics.com.

Safe harbor statement

This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements can be
identified by the use of forward-looking terminology, including "may,"
"believe," "will," "expect," "anticipate," "estimate," "plan," "intend,"
"forecast," or other similar words. Statements contained in this press
release are based on information presently available to us and assumptions
that we believe to be reasonable. We are not assuming any duty to update this
information if those facts change or if we no longer believe the assumptions
to be reasonable. Investors are cautioned that all such statements involve
risks and uncertainties, including without limitation, statements concerning
completing the current and future share repurchase programs. Our actual
results may differ materially. Important factors that may cause actual
results to differ include, but are not limited to: continued market acceptance
of VNS Therapy™ and sales of our products; the development and satisfactory
completion of clinical trials and/or market test and/or regulatory approval of
new products, including VNS Therapy™ for the treatment of other indications;
satisfactory completion of the post-market registry required by the U.S. Food
and Drug Administration as a condition of approval for the treatment-resistant
depression indication; adverse changes in coverage or reimbursement amounts by
third-parties; intellectual property protection and potential infringement
claims; maintaining compliance with government regulations and obtaining
necessary government approvals for new products and indications; product
liability claims and potential litigation; reliance on single suppliers and
manufacturers for certain components; the accuracy of management's estimates
of future expenses and sales; the potential identification of material
weaknesses in our internal controls over financial reporting; and other risks
detailed from time to time in our filings with the Securities and Exchange
Commission (SEC). For a detailed discussion of these and other cautionary
statements, please refer to our most recent filings with the SEC, including
our Annual Report on Form 10-K for the fiscal year ended April 27, 2012 and
our Quarterly Report on Form 10-Q for fiscal quarters ended July 27, 2012 and
October 26, 2012.

Contact information

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main: (281) 228-7262
Fax: (281) 218-9332
ir@cyberonics.com



SOURCE Cyberonics, Inc.

Website: http://www.cyberonics.com